New Antifungal Option for Cancer Patients

Explore a groundbreaking phase III study on isavuconazole, a novel antifungal medication for cancer patients with invasive mold disease. Learn about its efficacy compared to voriconazole and its improved side effect profile. Delve into the research methodology, including double-blind trials and drug level assessments. Discover the challenges faced during the study, FDA approval process, and the implications for future antifungal treatments. Gain insights from experts Kieren Marr of Johns Hopkins University and Andrew Ullmann of Julius Maximilians University as they present their findings and discuss the potential impact on cancer patient care.

Introduction
Welcome
Study Overview
Uncontrolled Cancer
Drug Target
Side Effects
First Events
Double Blind
Padova
FDA Approval
AE Profile
Results
Severe Adverse Events
Drug Levels
Poster Presentations
New Side Effects
Adverse Events
Inferiority Trials
Challenges